Thalidomide and lenalidomide (IMID’s) in epithelioid hemangioendothelioma.
| Author | Reference | Age (years) | Gender (M/F) | IMID | Dose and schedule | Outcome | Follow-up |
|---|---|---|---|---|---|---|---|
| Salech F el al. | 13 | 40 | F | Thalidomide | 300mg daily | Partial response | 109 months |
| Raphael el al. | 14 | 53 | F | Thalidomide | 400 mg daily | Stable disease | 84 months |
| Kassam el al. | 15 | 13 | F | Thalidomide | 400 mg twice a day | Progressive disease | _ |
| Bolke et al. | 16 | 47 | M | Thalidomide | ? | Progressive disease/death | -- |
| Mascarenhas el al. | 17 | 52 | M | Thalidomide | ? | Partial response | -- |
| Sumrall et al. | 18 | 31 | F | Lenalidomide | 25 mg daily for 21/28 days | Stable disease | 48 months |